J&J Acquires Rights to IBD Experimental Drug from Vedanta

J&J Acquires Rights to IBD Experimental Drug from Vedanta
johnson-johnsonJanssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has signed a license agreement with Vedanta Biosciences to acquire the rights for an investigational therapeutic alternative for the treatment of inflammatory bowel diseases (IBD), as announced by the companies in a recent press release. The novel IBD drug has been developed by Vedanta and is expected to modify the way in which the body's immune system and microbes interact with one another. The transaction between the two companies may provide Vedanta with up to $241 million of capital, which includes not only the acquisition rights for the experimental treatment VE202, but also an upfront payment and additional ones in case of approval of the medication for the treatment of conditions like ulcerative colitis (UC) or Crohn’s disease. Even though VE202 has yet to be tested in human trials, the experimental therapy has revealed its efficacy in previous preclinical studies conducted in both animals and models of autoimmune diseases. Johnson & Johnson will now continu
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *